DUBLIN, Aug. 9, 2022 /PRNewswire/ — The “Telehealth Kiosk Market – Global Outlook and Forecast 2022-2027” report has been added to ResearchAndMarkets.com’s offering.
The global telehealth kiosk market is expected to grow at a CAGR of 19% during 2022-2027.
The positive results of telehealth kiosk are widespread in reducing medical costs. Nursing is at the forefront of achieving these results and was one of the first users of healthcare IT to feature patient involvement. Hospitals are increasingly generating revenue from using telehealth kiosks, helping them relentlessly focus on improving patient outcomes.
The adoption of telehealth kiosks in developed countries is higher than in developing countries. Some key players in the telehealth kiosk market strive to combine customer suggestions for patient experience, patient satisfaction, and patient outcomes. Stakeholders in the telehealth kiosk market are pushing these proposals to attract healthcare providers and patients.
Telehealth kiosks aim to break barriers and provide equal access to medical services and interventions. They can help overcome obstacles of a face-to-face consultation, including schedule issues, bad weather, and illness. It also allows patient tracking and monitoring. The newest model is a Mobile telehealth kiosk that can provide instant access to the people in remote places and can be moved to the areas where it is required. It facilitates consumers to access health information consultation support.
KEY HIGHLIGHTS OF THE GLOBAL TELEHEALTH KIOSK MARKET
The introduction of digital platforms in healthcare has made consultations and procedures a simple task for healthcare professionals to perform due to better connectivity. This is increasing the adoption of telehealth kiosks. The technological advancements and rising global investments in telehealth are helping the end-users in terms of time management, cost of care, and remote monitoring in emergencies.
Developed countries like the US, the UK, France, and Japan are the major contributors to telehealth platform adoption. The increasing prevalence of chronic disease patient population is hitting the demand for healthcare services, accelerating the adoption of telehealth to provide patient-centric care.
Market players are offering advanced telehealth solutions to fulfill the unmet needs of traditional healthcare platforms. New players are emerging in the market with some digital-non-healthcare players, which is increasing the adoption of remote monitoring of patients. The market will provide enormous opportunities for the emerging players during the forecast period.
Potential and technological advancements in Telehealth Kiosk Market
Specialty-specific telehealth kiosk are also introduced in the market; Mental health telehealth kiosk have customized solutions for the patients. This kiosk technology can potentially improve the quality of health care and make it accessible to more people. Telehealth kiosk provide an opportunity to coordinate healthcare more efficiently, better, and closer to home.
For example, studies have shown that providing telephone support and remote monitoring of vital signs to people with heart failure reduces the risk of death and hospitalization. This helps to improve the quality of patient life. Clinical usage of remote healthcare technologies includes transmitting medical images for diagnosis & disease management, and individuals or groups can help provide better care.
The rising burden of chronic diseases
Chronic diseases and seasonal flu illnesses are on the rise around the world. The aging population and changes in lifestyle have contributed to the steady increase in these common and costly long-term health problems. Emerging economies hit hardest; telehealth kiosk provide the ideal solutions by increasing access to healthcare solutions. Access to medical needs has become a significant problem in many developing countries.
Rising investment in digital health
The companies are raising plenty of cash in the funding rounds. The digital health companies raised $57.2 billion worldwide in 2021 with 2,930 deals, increasing 79% from 2020. While digital health investments covered many functional areas and offerings, start-ups in the biopharma and MedTech R&D space gained the highest funding. In contrast, the mental health and diabetes specialty segment saw increased investments.
COVID-19 IMPACT
The COVID-19 pandemic has pushed the world and its economic situation into difficult market conditions. COVID-19 pandemic primarily increased the adoption of telehealth kiosk.
Many hospitals have seen an increase in tele consultations.. Especially chronic disease management, post-surgical visits, pediatric care, and mental health consultations have significantly shifted towards using Telehealth kiosk. The stalls can reduce overcrowding in emergency rooms, provide emergency consultations and general maintenance, and save on medical facility costs.
The adoption of telehealth kiosk has been one of the most important developments in healthcare during the pandemic. As the COVID-19 epidemic spreads exponentially around the world, the adoption of telehealth was also clearly seen in the countries.
Applications Insights
The applications in the telehealth kiosk market are segmented by teleconsultation, vital sign monitoring, digital pharmacies, and others. The teleconsultation segment dominated the market in 2021 and is expected to grow healthy during the forecast period. Teleconsultations are the most preferred health solutions to avoid waiting, low cost and reduce travel time.
Many large independent pharmacies are installing the telehealth kiosk, which motivates the patients to take up the teleconsultation visits through the stalls and to take medicine directly from the pharmacies. This will increase the sales of drugs in the pharmacies and increase access to healthcare treatments. The author predicts pharmacies will generate double the revenue by 2025 compared to 2021.
End-user Insights
Telehealth platforms are already being adopted by some healthcare facilities concerned with better patient care. The impact of the COVID-19 shifted the adoption rate of telehealth. The surveys showed that patients are ready to utilize telehealth platforms for consultations, second opinions, and medications. This shows healthy growth of the telehealth kiosk market among the end-user segments.
GEOGRAPHICAL ANALYSIS
North America dominated the global telehealth kiosk market and is expected to grow at a healthy growth rate during the forecast period. US and Canada are significant contributors to the market. The region’s adoption rate of advanced healthcare solutions is high due to better healthcare infrastructure and the rising chronic diseased population. The adoption of telehealth gives opportunities to non-healthcare IT players to enter the healthcare sector.
Europe is the second-largest region to contribute to the telehealth kiosk market. The presence of market players and the adoption of telehealth services in the area is growing at a healthy rate. Increasing incidences of chronic diseases in the region are shifting the adoption of telehealth solutions.
APAC is still developing in terms of digital healthcare adoption. It offers a huge opportunity for market players in the region due to the demand and usage of telehealth solutions. This region has a presence of emerging players in the market and is expected to offer better opportunities for them.
Latin America, the Middle East & Africa are slow in adopting advanced healthcare solutions. African countries have a vast potential for these technologies, which will help increase access to medical consultation. This region is also investing slowly in advanced healthcare solutions. The digitalization of healthcare in these regions will make it possible to offer better patient outcomes. The market players are shifting their focus to providing economical solutions in low-income countries
MARKET DYNAMICS
Market Opportunities & Trends
Telehealth Kiosks for Point-Of-Care Consultation
Next-Generation Telehealth Kiosks Transforming Healthcare Solutions
Digital Tools for Affordable Telehalth
Market Growth Enablers
Ongoing Covid-19 Pandemic & Adoption of Telehealth Kiosks
Rising Burden of Chronic Diseases & Hospitalization Rates
Virtualization Within Healthcare
Market Restraints
Chances of Misdiagnosis Due to Lack of Physical Examination
Dearth of Specific Regulations Worldwide
High Cost of Telehealth Kiosk Equipment
VENDOR LANDSCAPE
Key Vendors
CSI Health
IDOCTORCLOUD
KIOSK Information
Olea Kiosk
Sonka Medical
Other Prominent Vendors
19 LABS
Advantech
Apollo Telehealth
Bewell Connect
Clinics On Cloud
DoctorTouch
H4D
Howard
IPM France
ImedTac
Instapract
Let’s Talk
Meridian Kiosk
OnMed
TalkBox Booth
TelaCare Health
Voice Products
Yolo Health
For more information about this report visit https://www.researchandmarkets.com/r/kympjc
Media Contact:
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/global-telehealth-kiosk-markets-2022-2027—virtualization-within-healthcare-telehealth-kiosks-for-poc-consultation-ongoing-covid-19-pandemic–adoption-of-telehealth-kiosks-301602437.html
SOURCE Research and Markets
Does high risk mean high reward? Not necessarily, so say the pros on Wall Street. Specifically citing penny stocks, or stocks that trade for less than $5 per share, analysts advise caution as these names might still be in the early innings, or it could be that they face an uphill battle that is just too steep. Luring investors with their bargain price tags, these stocks might be up against overpowering headwinds or have weak fundamentals. However, analysts argue there are early-stage companies t
Acadia Pharmaceuticals Inc (NASDAQ: ACAD) stopped working on two candidates, including a one-time competitor to Vertex Pharmaceuticals Incorporated's (NASDAQ: VRTX) non-opioid painkiller. The company scrapped the ACP-044 program after evaluating the final phase 2 data on bunion removal patients. Initial data announced in April showed that the primary endpoint of pain intensity was not met. Rival Vertex boasted a mid-phase win for a similar candidate. Acadia has also discontinued ACP-319, which w
Is Johnson & Johnson stock a sell after cutting its 2022 outlook amid currency concerns? Is JNJ stock a sell right now?
Half of people with possible cancer symptoms do not contact their GPs for six months, according to a survey.
The Weis Health Ambassador program provides basic health care skills, guest speakers and events to help students pursue a career in health care.
Parenting can often feel like a never-ending list of dos and don’ts. It’s understandable—we are all trying our best to safeguard our kids from harm and help them grow up into happy, healthy humans. And while…
MR.Cole_Photographer via GettyA group of Boston researchers have designed a postcard-sized test that can detect both a SARS-CoV-2 infection and the presence of antibodies as a result of recent infection—providing a two-in-one punch that can both diagnose active COVID cases (including specifying which variant is responsible), as well as how well protected someone might be from future infections, thanks to antibody levels. The researchers hope their new portable device, which tests a patient’s sal
Biogen Inc. is looking to exit one of its buildings in Kendall Square and to sublease a sizable chunk of its space in Weston. The moves come as the Cambridge-based biotech company cuts costs amid struggles related to its Alzheimer's drug.
The Food and Drug Administration granted an emergency authorization that allows healthcare providers to give out the Jynneos monkeypox vaccine to adults intradermally instead of subcutaneously. Injecting the vaccine into an upper layer of the skin is expected to allow more doses of the vaccine developed by Bavarian Nordic to be made available to the public during the public health emergency. "Given the continued spread of the monkeypox virus at a rate outpacing the availability of our current va
U.S. health officials on Tuesday authorized a plan to stretch the nation’s limited supply of monkeypox vaccine by giving people just one-fifth the usual dose, citing research suggesting that the reduced amount is about as effective.
Actress Halle Berry, 54, showed off her toned back and legs in a new swimsuit photo. The actress is known for her hardcore workouts and following a keto diet.
Athersys Inc (NASDAQ: ATHX) has announced the results of a radiation countermeasure study that showed intravenous MultiStem (invimestrocel) administration provided benefit in an animal model of acute radiation syndrome (ARS). The results demonstrate that the administration of MultiStem cells increased survival in treated animals compared to vehicle treatment, resulting in higher body weights in surviving animals and positive trends in the recovery of the hematopoietic system. Also Read: Athersys
Is Pfizer stock a buy after the company announced its $5.4 billion plan to buy Global Blood Therapeutics? Is PFE stock a buy right now?
Two more people died of COVID-19, Shasta County Health and Human Services Agency announced Tuesday. Here's the latest:
Karuna Therapeutics topped expectations Monday in a study of its schizophrenia treatment, and the biotech stock soared to a record high.
Story at a glance Overall, 61 percent of adults over 50 are very likely to get an updated booster. The number is higher among particularly vulnerable groups as 68 percent respectively of people over 65, Black adults over 50 and people with low incomes are very likely to do so. About 17 percent of adults over…
Researchers are seeking thousands of volunteers in the U.S. and Europe to test the first potential vaccine against Lyme disease in 20 years — in hopes of better fighting the tick-borne threat.
Eli Lilly & Co. says Indiana's antiabortion law will hurt its hiring. That comes after the company donated to the politicians behind the law.
The FDA approved Bayer AG's (OTC: BAYRY) supplemental marketing application for Nubeqa (darolutamide) with docetaxel for metastatic hormone-sensitive prostate cancer (mHSPC). The approval is based on the results of Phase 3 ARASENS trial that demonstrated a reduction in the risk of death by 32% in Nubeqa plus androgen deprivation therapy and docetaxel compared to ADT and docetaxel. Nubeqa plus ADT and docetaxel also resulted in a statistically significant delay in time to pain progression. The re
Eli Lilly said the new abortion law could hinder its ability to “attract diverse scientific, engineering and business talent from around the world.”
